1310554-93-8

Upstream product

• 864948-63-0 (+)-(1R,2R,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakisbenzyloxycyclohexanol 
• 1287225-25-5 (1R,2R,3S,4R,5R,6S)-2-amino-3,4,5,6-tetrakis(benzyloxy)cyclohexanol 
• 1310554-91-6 N-((1R,2S,3R,4R,5S,6R)-2,3,4,5-tetrabenzyloxy-6-hydroxycyclohexyl)carbamic acid tert-butyl ester 
• 868549-83-1 (1R,2R,3S,4R,5S,6S)-2,3,4,5-tetrakis(benzyloxy)-6-(tert-butoxycarbonylamino)cyclohexyl methanesulfonate 
• 868549-84-2 N-((1R,2S,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakis(benzyloxy)cyclohexyl)carbamic acid tert-butyl ester 

Downstream Products

• 1310554-94-9 (1R,2S,3S,4R,5R,6S)-2-azido-3,4,5,6-tetrakis(benzyloxy)-N-nonylcyclohexanamine 

Relevant academic research and scientific papers

The myo-1,2-diaminocyclitol scaffold defines potent glucocerebrosidase activators and promising pharmacological chaperones for gaucher disease

A series of cyclitol derivatives with myo-configuration are β-glucocerebrosidase (GCase) inhibitors and show excellent characteristics for the development of pharmacological chaperones for enzyme deficiency in Gaucher disease (GD). The most potent inhibit